Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Heckel, Martina | Kieseier, Bernd C. | Schaper, Joerg | Mayatepek, Ertan | Rosenbaum, Thorsten
Affiliations: Department of General Pediatrics, University Children's Hospital, Duesseldorf, Germany | Department of Neurology, University Children's Hospital, Duesseldorf, Germany | Department of Diagnostic Radiology, University Children's Hospital, Duesseldorf, Germany
Note: [] Correspondence: Dr. Martina Heckel, Department of General Pediatrics, University Children's Hospital, Heinrich-Heine-University Düsseldorf Moorenstr. 5, D-40225 Düsseldorf, Germany. Tel.: +49 211 811 7687; Fax: +49 211 811 8757; E-mail: [email protected]
Abstract: Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system of unknown etiology. In the acute phase, MS is treated with corticosteroids, whereas drugs, such as interferon-beta and glatiramer acetate, are currently used as continuous immunomodulatory therapies. Recently, the cytostatic drug mitoxantrone was reported to be well tolerated and therapeutically effective in deteriorating MS in adults. Under the concept of an escalating therapy regimen, we addressed if mitoxantrone could decrease the frequency of relapses and stabilize the course of the disease not only in adults but also in children. Two adolescents (female 13 yrs.; male 14 yrs.) with deteriorating relapsing-remitting MS were selected after various immunomodulatory treatments had failed before. After informed consent had been obtained from the parents and the patients, we administered mitoxantrone intravenously in three-month intervals for 3.5 years and 12 months, respectively. Therapy with mitoxantrone was well tolerated in both patients. In the female patient a decrease in the number of relapses, and an improvement in clinical disability as measured by the Expanded Disability Status Scale was observed. In the male patient, a stabilization of the clinical course was achieved. We conclude that treatment with mitoxantrone could be considered in children with deteriorating MS when other therapeutic agents have failed. However, controlled studies in the pediatric age group are needed in order to assess the benefit of this chemotherapeutic agent and to rule out long-term adverse effects.
Keywords: Mitoxantrone, children, multiple sclerosis, escalating therapy
Journal: Journal of Pediatric Neurology, vol. 3, no. 4, pp. 237-242, 2005
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]